Southeast Asia Malaria Research Center: Malaria epidemiology study in Thailand and Myanmar - A supplement Program for Malaria Elimination Strategy

Not Applicable

Recruiting

• Conditions: Malaria; Malaria elimination; Vivax malaria; Mass primaquine preventive treatment

• Registration Number: TCTR20190806004
• Lead Sponsor: Faculty of Tropical Medicine, Mahidol University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-08-06
• Study Completion: 2021-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 4000

Inclusion Criteria

For Observational study:
1. Both male and female
2. Age 18 years old or above

For Implementation study:
1. Both male and female
2. Age 1 year old or above

Exclusion Criteria

For Observational study:
1. Not willing to participate in the study
2. Unable to provide information either due to physical or mental conditions

For Implementation study:
Regarding participating in cohort
1. Not willing to participate in the study
2. Mental Illness and prisoners
Regarding drug administration:
1. Not willing to take primaquine
2. Pregnant and lactating women
3. For those age 7 years or older who has G6PD abnormal
4. Have history of allergy to primaquine
5. Have history of drug reaction, such as hemolysis or dark urine, after having primaquine

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in malaria incidence Year 1 = Month 1, Month 5 and Month 9; Year 2 = Month 1, Month 5 and Month 9; Passive Case Detectio a) The clinical malaria incidence rates, b) the Plasmodium prevalence rates,Cost estimates for MPPT implementation Monthly/Real time Costs spent for intervention and additional MPPT activities

Secondary Outcome Measures

Name	Time	Method
Baseline prevalence of G6PD deficiency in the study population Prior to PQ administration for each group G6PD-RDT,Rates of primaquine-induced hemolysis in females Day 1, 2, 4, 6, 7 and 28 of PQ treatment Hemoglobin level,Impact of MPPT on parasite genetic diversity and relapse rates Year 1 = Month 1, Month 5 and Month 9; Year 2 = Month 1, Month 5 and Month 9; Passive case detectio Genotyping by deep sequencing of malaria parasites,Morbidity data 6-month prior to MPPT (PQ administration), during 1st and 2nd MPPT, 6-month after MPPT intervention Monthly morbidity data of reportable diseases from the surveillance system